Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jun 7;131(23):2596-2598.
doi: 10.1182/blood-2017-12-822940. Epub 2018 Apr 18.

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W Laetsch  1   2 , Shannon L Maude  3   4 , Michael C Milone  5   6 , Kara L Davis  7 , Joerg Krueger  8 , Ana Maria Cardenas  6   9 , Lamis K Eldjerou  10 , Christopher H Keir  10 , Patricia A Wood  10 , Stephan A Grupp  3   4
Affiliations
Case Reports

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W Laetsch et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: T.W.L. reports personal fees from Loxo Oncology, Eli Lilly, and Novartis Pharmaceuticals Corporation, and grants from Pfizer Inc, outside the submitted work. S.L.M. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. M.C.M. reports grants from Novartis Pharmaceuticals Corporation, outside the submitted work, and is an inventor on granted and pending patents related to tisagenlecleucel and CTL119 that are owned by the University of Pennsylvania and licensed to Novartis. K.L.D. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. L.K.E. reports employment by Novartis Pharmaceuticals Corporation. C.H.K. and P.A.W. report employment by and equity ownership in Novartis Pharmaceuticals Corporation. S.A.G. reports grants and personal fees from Novartis Pharmaceuticals Corporation, Jazz Pharmaceuticals, and Adaptimmune Therapeutics, outside the submitted work, and holds a patent with royalties paid by Novartis Pharmaceuticals Corporation. The remaining authors declare no competing financial interests.

References

    1. Garfall AL, Maus MV, Hwang WT, et al. . Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047. - PMC - PubMed
    1. Maude SL, Frey N, Shaw PA, et al. . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. - PMC - PubMed
    1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733. - PMC - PubMed
    1. Milone MC, Fish JD, Carpenito C, et al. . Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-1464. - PMC - PubMed
    1. Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J. 2012;443(3):603-618. - PubMed